TOVX
Theriva Biologics, Inc. (TOVX) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
TOVX’s R&D intensity is materially higher than diversified peers, which can support lower process emissions per innovation dollar but also raises lab-resource and waste-management scrutiny.
The company’s capital-light leverage profile is better than many biotech peers, which can reduce financing pressure for environmental controls but does not itself indicate superior environmental management.
No disclosed emissions, energy, water, or waste metrics were provided, so relative environmental positioning versus peers remains difficult to verify and is likely driven more by disclosure depth than performance.
As a development-stage biotech, TOVX’s environmental footprint is typically smaller than manufacturing-heavy peers, but its limited operational disclosure weakens confidence in any peer-leading assessment.
Social
TOVX’s high R&D-to-revenue ratio suggests a science-intensive operating model, which can support specialized talent retention relative to commercial-stage peers but also increases dependence on scarce expertise.
Stock-based compensation at 2.17% of revenue is modest versus many early-stage biotech peers, which can indicate somewhat better alignment and lower dilution-related employee friction.
No workforce, safety, clinical-trial, patient-access, or community metrics were provided, limiting evidence that TOVX manages social risks better than peers.
Because social materiality in biotech is driven by trial conduct, patient safety, and disclosure quality, the absence of those data keeps TOVX in a mid-pack relative position.
Governance
TOVX’s debt-to-equity ratio of 0.29 and net debt-to-EBITDA of 0.67 suggest comparatively restrained leverage, which can reduce creditor pressure and governance stress versus more indebted peers.
The low stock-based compensation burden is a positive governance signal relative to many small-cap biotech peers, because it can imply less aggressive dilution and compensation risk.
No board composition, audit, insider-ownership, or controversy data were provided, so governance quality cannot be confirmed beyond balance-sheet discipline.
Given the limited disclosure set, TOVX appears neither structurally weak nor clearly leading on governance relative to peers, leaving it in a moderate position.
Overall Score
TOVX appears moderately positioned versus peers, with some balance-sheet and compensation discipline offset by limited ESG disclosure across all three pillars.
Score Driver: Limited ESG Disclosure Prevents A Stronger Peer-Relative Assessment Despite Some Favorable Capital And Compensation Indicators.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Theriva Biologics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
